Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

by Insa Winzenborg, Akshanth R. Polepally, Ahmed Nader, Nael M. Mostafa, Peter Noertersheuser, Juki Ng
Published 2020-08-01

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women

by Denise Beck, Insa Winzenborg, Wei Gao, Nael M. Mostafa, Peter Noertersheuser, Stephanie E. Chiuve, Charlotte Owens, Mohamad Shebley
Published 2021-07-01

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

by Ahmed Abbas Suleiman, Ahmed Nader, Insa Winzenborg, Denise Beck, Akshanth R. Polepally, Juki Ng, Peter Noertersheuser, Nael M. Mostafa
Published 2020-11-01

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

by Sven Stodtmann, Ahmed Nader, Akshanth R. Polepally, Ahmed A. Suleiman, Insa Winzenborg, Peter Noertersheuser, Juki Ng, Nael M. Mostafa, Mohamad Shebley
Published 2021-07-01